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a b s t r a c t
In the last few years, there has been a rapid increase in patients being treated with various
anticoagulation and antiplatelet agents. In clinical neurology, these drugs are administered
for primary and secondary stroke prevention or to avoid the consequences of immobiliza-
tion of severe stroke patients. Additionally, thrombolytic intravenous therapy and, recently,
intra-arterial therapy for stroke have been increasingly employed all over the world. These
therapies are associated with an increased risk of hemorrhage, including the most danger-
ous, intracranial hemorrhage. The knowledge of the standards for the treatment of hemor-
rhagic complications in the central nervous system is crucial for doctors in neurology and
stroke units as well as in emergency rooms. Therefore, we conducted a review of various
guidelines and recommendations, including manufacturers' opinions contained in the
summaries of product characteristics (Polish and British or European versions), in Guidelines
of the Polish Neurological Society and in international and American guidelines i.e., Euro-
pean Stroke Organization (ESO) and American Heart Association/American Stroke Associa-
tion (AHA/ASA). In addition, we compared these guidelines with expert opinions published
in recent manuscripts and manuals on intensive care in neurology.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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has rapidly increased, especially in secondary and primary
prophylactics for ischemic stroke as well as for avoiding the
consequences of immobilization in severe stroke patients.
In addition, in the last few years, there has been a
signiﬁcant increase in the number of stroke patients treated* Corresponding author at: Department of Neurology and Cerebrovascu
Hospital, Dojazd 34 Street, 60-631 Poznań, Poland. Tel.: +48 61 846 45
E-mail address: rkazmierski@umed.poznan.pl (R. Kaźmierski).
http://dx.doi.org/10.1016/j.pjnns.2015.06.003
0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Sintravenously and, more recently, intra-arterially with recom-
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The increase in the number of patients treated with these
drugs is related to the growth in the risk of antiplatelet-,
anticoagulation- and thrombolytic-associated intracranial
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treated with these drugs is crucial for every-day clinical
practice.
Unfortunately, the guidelines, recommendations and
strategies for the reversal of drug-induced coagulopathy in
cerebral hemorrhage are not consistent. Some of these
guidelines, recommendations and strategies do not consider
cerebral hemorrhage but merely refer to the general treatment
of any hemorrhage.
Therefore, we developed a summary of the recommenda-
tions from various up-to-date sources and attempted to
compare them.
The aim of this paper was to present the methods of
reversing the coagulopathy in intracranial hemorrhages
caused by the following:
 Anticoagulation agents: heparins, vitamin K antagonists,
and non-vitamin K antagonist oral anticoagulants (formerly
novel oral anticoagulants (NOACs)) (apixaban, rivaroxaban
and dabigatran),
 Antiplatelet agents, including acetylsalicylic acid (aspirin),
thienopyridines (as clopidogrel and prasugrel), and tica-
grelol.
 Thrombolytic agents (rtPA).
Because the methods of treatment of those coagulopathies
differ depending on the hemorrhage etiology, clinical center
experience and evidence from clinical trials, we developed a
summary of treatment recommendations from the following
sources: the summary of product characteristics (SPCs)
published by the manufacturer (Polish and British or European
versions), current guidelines by Polish (Polish Society of
Neurology – PTN) [1], European (ESO) [2], and American
(AHA/ASA) [3] scientiﬁc organizations and current manuals
by leading experts in the ﬁeld published within the last 3 years
[4–6].
The review involves primary intracranial hemorrhage
(ICrH) and secondary ICrH after ischemic stroke. A generally
accepted rule is that the hemorrhagic transformation of
ischemic stroke with deterioration of the neurologic condition
requires management that is similar to that in spontaneous
ICrH. Clinically insigniﬁcant secondary hemorrhages (diag-
nosed with neuroimaging methods) do not require any
additional measures [1].
We reviewed only pharmacological therapies, and the
indications for surgical treatment of ICrH will be addressed in
another review.Table 1 – The management of VKA-associated ICrH.
SPC [7–10] PNA [1] ESO [2] A
Withold oral anticuagu
Vitamin K p.o. or i.v.
PCC or FFP and vitamin K
(acenocumarol SPC only: whole
blood or rFVIIa + vitamin K)
When INR
is >1.4:
Vitamin K
PCC
Vitamin K i.v.
Add PCC or FFP
V
P
FFP – fresh frozen plasma, PCC – prothrombin complex concentrate, rFV1. Vitamin K antagonists (VKA)
See Table 1.
1.1. Summary of product characteristics
1.1.1. Acenocoumarol
Summary of product characteristics, Polish version (2013) [7],
outlines therapeutic options in hemorrhage after acenocoumarol
administration. In clinically insigniﬁcant hemorrhages – tempo-
rary reduction of the dose. In moderate hemorrhages – vitamin K
2–5 mg p.o. In severe hemorrhages – vitamin K 5–10 mg i.v. (not
faster than 1 mg/min). This dose can be repeated every 4 h up to a
daily dose of 40 mg. In the case of sudden severe hemorrhage –
fresh whole blood or fresh frozen plasma (FFP) or recombinant
Factor VIIa (rFVIIa) and vitamin K should be administered.
Additionally, in British version of SPC [8], manufacturer
recommends management of severe hemorrhage with
administering fresh whole blood or prothrombin complex
concentrate (PCC) with vitamin K.
1.1.2. Warfarin
Therapeutic options for warfarin (tabl. a 3 and 5 mg) described
in summary of product characteristics, Polish version (2013) [9]
are as below:
Warfarin's half-life is 20–55 h; therefore, overdoses require
longer observation and longer vitamin K administration. In
some cases, gastric lavage and activated charcoal p.o. may be
useful. If severe bleeding occurs, FFP, PCC or tranexamic acid
can be administered.
Manufacturers outline the management of INR increases;
this management may be considered ICrH prevention. An INR
increase does not automatically lead to a hemorrhage, but it is
a deﬁnite ICrH risk factor; therefore, below, we present the
management of such a condition.
INR > 4 without bleeding – stop warfarin, wait 1 day, adjust
the dose. INR > 6 without bleeding – stop warfarin, wait 1–2
days, adjust the dose, check the INR immediately. INR > 8
without bleeding – stop warfarin, consider administering
1–2 mg of vitamin K i.v. or p.o., wait – 2 days, check the INR the
following day, adjust the dose.
Small bleeding * – stop warfarin, wait 1–2 days before using
warfarin and consider administering 1–2 mg of vitamin K i.v.
or p.o.
Severe bleeding* – stop warfarin, rapidly reduce the INR to
1.5–1.6; 10 ml/kg FFP can reduce INR from 7 to 4 or from 4 to 2.2.HA/ASA [3] Manual
Wijdics [4]
NCC
Wijdics [5]
Manual
Frontera [6]
lant administration
itamin K i.v.
CC, FFP
Vitamin K i.v.
PCC, FFP or
rFVIIa
Vitamin K i.v.
PCC, FFP or
rFVIIa
Vitamin K i.v.
PCC or FFP
IIa – recombinant factor VIIa.
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immediate but is reduced after 6 h.
If the treatment with warfarin can be stopped, vitamin
K 5–10 mg i.v. should be used together with PCC/FFP or vitamin
K 2–5 mg i.v. if warfarin will be continued.
An effect of vitamin K is often observed within 6–12 h, with
the maximal effect after 24 h.
Intoxication – in the case of bleeding see above.
Therapeutic options: vitamin K at a dose 10 mg i.v. should
be administered 3–4 times per day until the time of the
expected elimination of the warfarin effect.
Treatment should be up to a few days.
In British version of SPC [10] manufacturer speciﬁes slightly
different management of warfarin intoxication as well as of
INR increases.
For patients on long-term anticoagulants:
INR > 8.0, no bleeding or minor bleeding – stop warfarin,
give vitamin K 0.5–1 mg i.v.; repeat dose of vitamin K if INR still
too high after 24 h.
INR 6.0–8.0, no bleeding or minor bleeding – stop warfarin,
restart when INR <5.0.
INR < 6.0 but more than 0.5 U above target value – reduce
dose or stop warfarin, restart when INR < 5.0.
For patients not on long-term anticoagulants without
major hemorrhage: measure the INR at presentation and
sequentially every 24–48 h after ingestion depending on the
initial dose and initial INR.
If the INR remains normal for 24–48 h and there is no
evidence of bleeding, there should be no further monitoring
necessary.
Give vitamin K if the patient has ingested more than
0.25 mg/kg or the prothrombin time is already signiﬁcantly
prolonged (INR > 4.0). The adult dose of vitamin K is 10–20 mg
orally. Delay oral vitamin K at least 4 h after any activated
charcoal has been given. Repeat INR at 24 h and consider
further vitamin K.
*SPC does not provide deﬁnitions for ‘‘small’’, ‘‘moderate’’,
‘‘severe’’ and ‘‘life-threatening’’ bleeding.
1.2. Polish Neurological Association
According to the guidelines of the Polish Neurological Association
[1] there are following options of management of oral
anticoagulant-associated intracerebral hemorrhage (ICeH) in
patients being administered oral anticoagulants whose INR is
greater than 1.4.
Withhold anticoagulants.
The INR should normalize as a result of using PCC. In
addition, intravenous vitamin K should be administered.
Additional information: It is recommended to administer
PCC with vitamin K due to much longer half–life of warfarin
and acenocoumarol than PCC's half-life [1].
1.3. European Stroke Organisation
European Stroke Organization guidelines for the management of
spontaneous intracerebral hemorrhage [2] state that in anticoagu-
lant-associated intracerebral hemorrhage in the absence of
randomized controlled trials (RCTs), strong recommendations
cannot be made about how, when, and for whom to normalizecoagulation for patients with acute spontaneous ICeH who are
being administered anticoagulant drugs. Additional informa-
tion: clinical, observational and pharmacological data have led
to standard clinical practice in acute ICeH being the adminis-
tration of 5–10 mg of intravenous vitamin K to patients who
are on vitamin K antagonists or the administration of
intravenous protamine sulfate to patients on heparin. For
patients who are on vitamin K antagonists at the time of an
ICeH and have an elevated INR, anticoagulant medication
should be discontinued, intravenous vitamin K should be
administered, and either FFP (e.g., 20 ml/kg) or PCC (e.g., 25–
40 IU/kg) should be added to prevent hematoma expansion.
The risk of a thrombotic event occurring due to the
normalization of coagulation for periods of time shorter than
a week is considered to be low for most indications compared
with the possible beneﬁt of stopping hematoma expansion or
re-bleeding [2].
1.4. AHA/ASA
The Guideline for Healthcare Professionals from the American
Heart Association/American Stroke Association Guidelines for the
Management of Spontaneous Intracerebral Hemorrhage [3] outlines
therapeutic options for patients with ICeH whose INR is
elevated due to oral anticoagulants. The patients should have
their warfarin withheld. The patients should receive therapy
to replace vitamin K-dependent factors and correct the INR
and should receive intravenous vitamin K. PCCs have not
shown improved outcomes compared with FFP but may have
fewer complications compared with FFP and are reasonable to
consider as an alternative to FFP.
Recombinant FVIIa does not replace all clotting factors, and
although the INR may be reduced, clotting may not be restored
in vivo; therefore, rFVIIa is not routinely recommended as a
sole agent for reversal of the effect of oral anticoagulants in
ICeH.
Although rFVIIa can limit the extent of hematoma expan-
sion in noncoagulopathic ICeH patients, there is an increase in
thromboembolic risk with rFVIIa and no clear clinical beneﬁt in
unselected patients. Thus rFVIIa is not recommended in
unselected patients [3].
1.5. Manual by Wijdicks
Manual by Wijdicks (2014) suggests following therapeutic
options for warfarin anticoagulation effect reversal:
Vitamin K 5–10 mg i.v., FFP 10–30 ml/kg i.v. (optimal
dose is unknown), PCC 8–30 IU/kg i.v., rFVIIa–20–30 mg/kg i.v.
[4].
1.6. Neurocritical care
In Neurocritical Care E.F.M. Wijdicks and A.A. Rabinstein [5]
suggest treatment options to reverse the effects of warfarin:
Vitamin K 5–10 mg i.v.,
FFP 10–40 ml/kg i.v. (optimal dose is unknown),
PCC 25–50 U/kg i.v.,
rFVIIa–20–40 mg/kg i.v. #
# – the authors added that much lower doses (5–10 mg/kg)
may be sufﬁcient based on their experience.
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Associated Cerebral Hemorrhage by E.F.M. Wijdicks and A.A.
Rabinstein:
 Aggressively lower INR to normal (INR < 1.5).
 Aggressively control blood pressure (SBP < 160 mmHg).
 Consider ventriculostomy when INR < 1.5 and hemoven-
tricle with hydrocephalus.
 Monitor EKG/troponin if rFVIIa has been administered.
 Monitor X-ray of the chest for pulmonary inﬁltrates if FFP
has been used and consider diuretics [5].
Comments by E.F.M. Wijdicks and A.A. Rabinstein:
PCC or rFVIIa may be a more effective way to reverse
warfarin.
Vitamin K and FFP may be the only available option,
but the INR is corrected in only 1/3 of the patients within
12 h.
Neurosurgical evacuation of a hematoma should remain an
option, but only when the INR is less than 1.5 [5].
1.7. Manual by Frontera
Therapeutic options for warfarin coagulopathy are also
described in the chapter Antiplatelet- and anticoagulation-
associated intracranial hemorrhage by Rincon F., et al. in Decision
Making in Neurocritical Care by Frontera J.A. [6].
Vitamin K 10 mg i.v. over 10 min (monitor for hypotension/
anaphylaxis)*
PCC ** 50 U/kg i.v.
If PCC is unavailable, 15 cc/kg of FFP i.v. should be
administered.Table 2 – The management of NOACs-associated ICrH.
SPC [11–16] PNA [1] ESO [2] AHA/
Rivaroxaban No guidelines Activated
charcoal
No gu
Activated charcoal PCC, aPCC
or rFVIIa
Symptomatic treatment 
PCC, aPCCa or rFVIIa 
Dabigatran 
Adequate diuresis, dialysis 
PCC, aPCC or rFVIIa 
Apixaban 
Activated charcoal
FFP 
rFVIIa 
a aPCC – activated PCC.**PCC, which is also known as factor IX concentrates,
bebulin or proﬁlnine, contains factors II, VII, IX and X in
varying amounts. The half-life of PCC is 6–12 h [6].
Warfarin and emergency neurosurgical intervention. The
guidelines are as above, moreover consider rFVIIa *** 20–80 mg/
kg i.v.
 *Vitamin K requires 6–24 h for full reversal. The half-life of
recombinant factor VIIa is 2.6 h.
 ** The half-life of PCC is 6–12 h.
 *** The half-life of rFVIIa is 2.6 h, and many cases require
repeated doses [6].
2. Non-vitamin K antagonist oral
anticoagulants (NOACs), (also known as novel oral
anticoagulants or direct oral anticoagulants
(DOACs))
See Table 2.
2.1. Summary of product characteristics
2.1.1. Rivaroxaban (Xarelto)
In Polish [11] as well as in European [12] SPCs the manufacturer
states that rivaroxaban overdoses may lead to hemorrhagic
complications, including ICrH, and that there is no speciﬁc
antidote that able to reverse the rivaroxaban effect.
There are no speciﬁc recommendations concerning the
ICrH. There are some general recommendations in the case of
loss of large blood volume. In the case of rivaroxaban overdose,
one may consider the administration of activated charcoal toASA [3] Manual Wijdicks [4] Manual Frontera [6]
idelines Rivaroxaban Hemodialysis or modiﬁed
ultraﬁltration
Activated charcoal rFVIIa, PCC or FFP
Hemoperfusion with
activated charcoal
4 factor PCC
Dabigatran
Activated charcoal
Hemoperfusion with
activated charcoal
Hemodialysis
4 factor PCC
Apixaban
Activated charcoal
Hemoperfusion with
activated charcoal
4-factor PCC
FFP is contraindicated
rFVIIA – unclear
3 factor PCC – unclear
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control of the hemorrhage, it is possible to take the following
measures:
- Consideration should be given to the implementation of
appropriate symptomatic treatment, such as mechanical
compression, surgical intervention, ﬂuid administration,
hemodynamic support, and the transfusion of blood or its
components*.
*A comment by the review's authors is as follows: those
actions are aimed at counteracting the effects of the loss
of large blood volume, which is usually not the goal in
ICrH.
- If the above measures fail to stop the life-threatening
bleeding, one may consider the administration of PCC,
activated prothrombin complex concentrate (aPCC) or rFVIIa.
Currently, there is no clinical experience in administration of
these agents in patients on rivaroxaban. This advice is based
on limited nonclinical data. Depending on the intensity of
bleeding, one should consider repeating administration of
rFVIIa and increasing its dose.
- Protamine sulfate and vitamin K should not affect the
anticoagulant activity of rivaroxaban. There is no scientiﬁc
basis nor clinical experience that conﬁrms the beneﬁts of
anti-hemorrhagic drugs (desmopresin, aprotinin, tranexa-
mic acid, aminocaproic acid) in patients taking rivaroxaban.
- Due to the high degree of binding to plasma protein,
rivaroxaban is not dialyzable [11,12].
2.1.2. Dabigatran (Pradaxa)
Polish [13] and European [14] SPCs state alike that:
In the case of clinically signiﬁcant bleeding, dabigatran
should be withdrawn. Strict clinical monitoring (including
monitoring for signs and symptoms of bleeding or anemia) is
advised during the entire period of treatment with dabigatran,
particularly if there are other bleeding risk factors. In the case
of severe bleeding (including intracranial), treatment with
dabigatran should be discontinued, and the source of bleeding
should be determined.
There is no speciﬁc antidote for dabigatran. Due to renal
excretion of dabigatran, adequate diuresis should be main-
tained. Appropriate supportive treatment should be consid-
ered, e.g., surgical hemostasis, and plasma or blood volume
transfusion, depending on the physician decision. Com-
ment: this statement is due to extracranial hemorrhage.
According to low protein binding, dabigatran can be
removed by dialysis.
There are limited clinical data to justify the clinical utility of
this method under clinical conditions.
Additionaly European SPC states that (aPCC) (e.g., FEIBA) or
rFVIIa or concentrates of coagulation factors II, IX and X, may
be considered [14].
2.1.3. Apixaban (Eliquis)
Both European [15] and Polish [16] SPCs describes management
of apixaban overdose as below.
- As with the use of other anticoagulants, patients taking
this medicine should be carefully monitored for signs of
bleeding.- In the case of severe bleeding, drug administration should be
withdrawn.
- There is no antidote for apixaban. Overdoses of apixaban
may increase the risk of bleeding. In the case of hemorrhagic
complications, apixaban administration should be discon-
tinued, and the source of the bleeding should be determined.
- Appropriate treatment should be considered, i.e., surgical
homeostasis or transfusion of FFP.
- In controlled clinical trials, apixaban administered orally to
healthy people at doses of 50 mg per day during 3–7 days
(25 mg twice a day for 7 days or 50 mg once a day per 3 days)
(doses 10-times higher than maximal recommended dose)
did not have any clinically signiﬁcant adverse effects.
- The manufacturer states that in preclinical trials performed
in dogs, the administration of activated charcoal up to 3 h
after apixaban intake diminished apixaban effects. The
manufacturer recommends the consideration of activated
charcoal for overdose treatment.
- If life-threatening bleeding persists despite the above
measures, the administration of rFVIIa should be consid-
ered. Currently, there is no clinical experience on the
administration of rFVIIa in patients taking apixaban.
Administering another dose of rFVIIa and modifying the
dose based on the degree of reduction in bleeding should be
considered [15,16].
2.2. Polish Neurological Association
The guidelines of the Polish Neurological Association Vascular
Diseases Section Expert Group 2012 [1] outline that there are no
guidelines that refer to intracerebral hemorrhage after either
primary intracranial bleeding or secondary transformation of
ischemic stroke due to novel oral anticoagulants usage.
However, the authors indicate a lack of data, specifying when
to start treatment with novel oral anticoagulants after ICeH,
and they outline the lack of a speciﬁc antidote for NOACs [1].
2.3. European Stroke Organisation
European Stroke Organization guidelines for the management of
spontaneous intracerebral hemorrhage [2] state that there is no
speciﬁc antidote available for any of the NOACs, and clinical
experience with haemostatic agents in NOAC-associated
bleeding is limited. An expert opinion on management of
bleeding emergencies associated with DOACs (NOACs) therapy
has been published in consensus paper [17].
The relevant expert opinion according to above mentioned
consensus paper [17] is presented below.
Recommendations: In case of intracranial hemorrhage
associated with NOACs, the following measures are recom-
mended, similar to the approach in vitamin K antagonists-
associated bleedings: (1) Discontinue NOACs. (2) Within the
ﬁrst 2 h after the last intake of dabigatran, inhibition of the
drug uptake with activated carbon is recommended. For
rivaroxaban, the use of active carbon should also be taken
into account. For apixaban, the use of active carbon is
recommended within 3 h after last intake. (3) Single adminis-
tration of 30–50 U/kg PCC i.v. If no clinical effect, further
administration of aPCC or rFVIIa can be considered. (4)
Lowering blood pressure to below 140 mmHg. (5) In case of
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according to the guidelines may be considered after hemo-
static parameters have normalized: dabigatran: TT* < fourfold
URN, ECT < twofold URN, or hemoclot < 50 ng; rivaroxaban,
and apixaban: anti-Xa activity test < twofold URN in plasma or
rivaroxaban plasma level <100 ng/ml or apixaban plasma
level < 10 ng/ml on calibrated test systems and normal levels
for aPTT and PTZ [17].
*(TT – thrombin time; URN – upper range of normal; ECT –
ecarin clotting time; hemoclot – drug-speciﬁc test systems;
aPTT – partial prothrombin time; PTZ PT – prothrombin time).
2.4. AHA/ASA
A Guideline for Healthcare Professionals from the American
Heart Association/American Stroke Association Guidelines for the
Management of Spontaneous Intracerebral Hemorrhage [3] states
that there are no speciﬁc therapeutic guidelines for ICeH after
novel oral anticoagulants usage.
2.5. Manual by Wijdicks
Wijdicks (2014) # Apixaban Dabigatran Rivaroxaban
Oral activated Charcoal Yes Yes Yes
Hemodialysis No Yes No
Hemoperfusion with
activated charcoal
Possible Yes Yes
FFP No No No
Factor VIIa Unclear Unclear Unclear
3-factor PCC Unclear Unclear Unclear
4-factor PCC Possible Possible Possible
#Adapted from Kaatz S, Kouides PA, Garcia DA et al. Guidance on the
emergent reversal of oral thrombin and factor Xa inhibitors. Am J
Hematol 2012; 87 (Suppl. 1): S141–S145 after Wijdicks (2014) [4].
Comment: Wijdicks EFM (2014), in his manual (p.107)
‘‘Providing Acute Care’’, stated the following:
‘‘Reversal of thrombin inhibitors (dabigatran) has not been
clearly established. Recent guidance suggests discontinuation
of the drug and possible PCC or hemodialysis’’.
‘‘Activated charcoal could be administered, if the drug was
taken within hours of presentation’’
‘‘Hemodialysis and hemoperfusion can be considered in
patients with impaired renal function (dabigatran); however, it
is not effective with apixaban or rivaroxaban because they are
highly protein bound. Recombinant Factor VIIa does not
reverse the anticoagulant effect, but PCC has been shown toTable 3 – The management of heparins-associated ICrH.
SPC [18–24] PNA [1] ESO [2] AH
LMWH
PS
UFH
Heparin withdrawal
PS, FB, FFP
Stop heparin
PS
Stop heparin
PS
N
g
UFH – unfractionated heparin, LMWH – low-molecular-weight heparin, Pnormalize the prothrombin time (PT) in normal volunteers. It
is unclear whether it is effective to stop bleeding, but it has
been used in emergency situations’’ [4].
After the drug is discontinued, the anticoagulant effect is
absent after 2 days.
2.6. Manual Frontera
Manual by Frontera (2009) [6] gives treatment options in
coagulopathy due to direct thrombin inhibitor (dabigatran).
There is no direct reversal agent.
- Reduce plasma concentration with hemodialysis or modiﬁed
ultraﬁltration.
- Increase other factors with rFVIIa or PCC/FFP [6].
3. Heparins
See Table 3.
3.1. Summary of product characteristics
3.1.1. Enoxaparin
The Polish SPC states that in low-molecular-weight heparin
(LMHW) associated hemorrhage protamine sulfate or hydro-
chloride should be administered slowly – 1 mg of protamine per
1 mg of enoxaparin (if LMWH was administered within the last
8 h) or infusion of 0.5 mg protamine per 1 mg of enoxaparin (if it
was administered more than 8 h ago or if a second dose of
protamine was necessary). The administration of protamine
12 h after enoxaparin injection might not be necessary [18].
The British SPC for enoxaparin is similar to the Polish
version and additionally states that the maximum dose of
protamine is 50 mg. Decisions regarding the necessity and
dose of subsequent protamine injections should be based on
clinical response rather than measurement of anti Xa or anti
XIIa results [19].
3.1.2. Nadroparin
For nadroparin (Fraxiparin) the Polish SPC suggest 0.6 ml of
protamine sulfate per 950 U of nadroparine taking the drug
administration time into consideration [20].
3.1.3. Dalteparin
For dalteparin (Fragmin) the Polish [21] and British [22] SPCs
suggest the following treatment: 1 mg protamine per 100 U of
anti-Xa dalteparin, the SPC do not mention the time of LMWHA/ASA [3] Manual
Wijdicks [4]
NCC
Wijdicks [5]
Manual
Frontera [6]
o speciﬁc
uidelines
No speciﬁc
guidelines
No speciﬁc
guidelines
LMWH
Protamine
UFH
Stop heparin
Protamine
S – protamine sulfate, FB – fresh blood.
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on primary haemostasis it should be used only in an
emergency [21,22]. Protamine should be given by intravenous
injection over approximately 10 min [22].
Unfractionated heparin (UFH).
The Polish SPC [23] outlines that in insigniﬁcant bleeding
cases, heparin withdrawal is sufﬁcient. If more intensive
bleeding occurs, one should control coagulation time as
well as platelets and slowly (not faster than in 5–10 min)
administer 1% protamine sulfate solution (not more than
50 mg). Each mg of protamine sulphate neutralizes
approximately 115 U of heparin.In life-threatening cases
one should consider transfusing fresh blood or FFP. As there
are no speciﬁc recommendation for ICrH, above mentioned
could be implemented also to ICrH.
British version [24] is similar to the Polish one. Decreasing
amounts of protamine (1% w/v solution) are required as
time from the last heparin injection increases. Thirty
minutes after a dose of heparin, approximately 0.5 mg of
protamine is sufﬁcient to neutralize each 100 U of heparin.
Initiation of corrective therapy should not depend on
laboratory conﬁrmation of the diagnosis.
3.2. Polish Neurological Association
The guidelines of the Polish Neurological Association Vascular
Diseases Section Expert Group 2012 [1] state that the treatment
with heparin has to be discontinued and there is a need to use
protamine sulfate at a dose that depends on the dose of
heparin and on the time from the end of the heparin
treatment.
Additional information:
Standard dose is 1 mg protamine i.v. per 100 U of heparin.
If more than 30 min have elapsed since the injection of
heparin, lower doses of protamine will be necessary.
After 30–60 min; 0.5–0.75 mg protamine i.v. per 100 U of
heparin,
>60–120 min; 0.375–0.5 mg of protamine per 100 U of
heparin,
>2 h; 0.25–0.375 mg of protamine per 100 U of heparin [1].
3.3. European Stroke Organisation
According to The European Stroke Organization (ESO) guidelines
[2], in the absence of RCTs, ESO cannot make strong
recommendations about how, when, and for whom to
normalize coagulation for patients with acute spontaneous
ICeH who had been on anticoagulant drugs.
Additional information: Treatment with anticoagulant drug
has to be discontinued, additionally ESO stated that: clinical
observational and pharmacological data have led to standard
clinical practice in acute ICeH being the administration of
intravenous protamine sulfate to patients on heparin [2].
3.4. AHA/ASA
Guidelines for Healthcare Professionals from the American
Heart Association/American Stroke Association [3] do not suggest
any speciﬁc therapeutic guidelines.3.5. Manual by Frontera
The manual by Frontera outlines the following therapeutic
options:
3.5.1. UFH
Stop infusion, no further action for minor bleeding. For severe
or intracranial bleeding, use protamine. Dosage of protamine
is based on the time from the last heparin dose.
Protamine maximum dose 50 mg, maximal infusion rate
5 mg/min.
Timing: (the half life of heparin is 2 h).
0–30 min; 1.0 mg protamine i.v. per 100 U of heparin;
31–60 min; 0.75 mg protamine i.v. per 100 U of heparin;
61–120 min; 0.5 mg of protamine per 100 U of heparin;
>2 h; 0.4 mg of protamine per 100 U of heparin.
3.5.2. LMWH
One milligram of protamine i.v. per 1 mg of LMWH adminis-
tered in the last 8 h; if bleeding persists, administer an
additional 0.5 mg of protamine i.v. per 1 mg of LMWH in the
last 8 h.
(No protamine if >8 h from dose).
Important Remarks: Protamine reverses only 60–75% of the
effect of enoxaparin. Protamine has minimal efﬁcacy against
danaparoid or fondaparinux [6].
4. Recombinant tissue plasminogen activator
(rtPA)
See Table 4.
4.1. Summary of product characteristics
Polish and British [25,26] SPCs state that if life-threatening
bleeding occurs, particularly ICeH, thrombolytic treatment
should be withdrawn. However, based on the short half-life of
alteplase and its small inﬂuence on the coagulation system,
there is no need for coagulation factor repletion. In the
majority of patients with bleeding, management is based on
thrombolytic and anticoagulation treatment withdrawal, ﬂuid
restoration and closure of the bleeding vessels (if possible).
If heparin was administered, protamine administration
may be considered up to 4 h after heparin usage. In patients
who do not respond to conventional methods, it is advisable to
transfuse blood products. Cryoprecipitate, fresh frozen plas-
ma, and blood platelets should be transfused, and following
each transfusion, the clinical and laboratory parameters
should be controlled. After cryoprecipitate transfusion, a
ﬁbrinogen concentration of 1 g/l should be achieved. Anti-
ﬁbrinolytic agents should be considered as the last resort. If
severe bleeding occurs, the infusion of FFP or fresh blood is
recommended [25,26].
4.2. Polish Neurological Association
The guidelines of the Polish Neurological Association (Vascular
Diseases Section Expert Group 2012) [1] state that asymptomatic
ICrH does not require additional treatment.
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n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 2 7 8 – 2 8 9 285Symptomatic secondary intracranial hemorrhage with the
deterioration of neurologic condition requires management
that is identical to that in spontaneous intracranial hemor-
rhage.
In the case of hemorrhagic transformation of ischemic
stroke, thrombolytic, antithrombotic and antiplatelet treat-
ment should be discontinued.
To minimize the risk of hemorrhagic transformation,
the maintenance of good control of blood pressure is
advised.
When hemorrhagic transformation is due to thrombolytic
therapy in the case of life threatening complications,
thrombolysis should be withdrawn.
In the case of persisting hemorrhage, measures designed
to restore hemostasis should be implemented, i.e., the
administration of 6–8 U of blood platelet concentrate, 12 U of
cryoprecipitate with factor VIII or FFP.
Neurosurgical treatment indications are similar to those in
other types of ICeH [1].
4.3. European Stroke Organisation
The ESO guidelines for the management of spontaneous intracerebral
hemorrhage [2] give no recommendations about pharmacologi-
cal treatment of intracerebral hemorrhage after rtPA. There is
also no evidence to support surgical intervention on a routine
basis for improving outcome after supratentorial ICeH
compared with conservative management, but early surgery
may be of value for patients with a Glasgow Coma Scale score
of 9–12 [2].
4.4. AHA/ASA
The AHA/ASA [27] states that although no study has been
conducted to determine the best way to manage post–
intravenous rtPA hemorrhage, many rtPA-associated hemor-
rhage protocols recommend the use of cryoprecipitate to
restore decreased ﬁbrinogen levels.
A recent case report described the use of tranexamic acid
for the treatment of an intravenous rtPA-associated hemor-
rhage in a Jehovah's Witness stroke patient. After adminis-
tration, no further hematoma expansion was noted [28].
Further studies are clearly warranted to deﬁne the optimal
approach to the management of ﬁbrinolytic-associated
hemorrhages.
Standardized guidelines for managing ﬁbrinolytic-associ-
ated hemorrhages do not exist. Given insights from clinical
trials, protocols recommend performing an emergent unen-
hanced computed tomography scan and taking blood samples
for measuring complete blood count, coagulation parameters
(PT, PTT, INR) and ﬁbrinogen levels. Concurrently, other causes
of neurological decline, such as hemodynamic instability,
should be pursued [27].
4.5. Manual by Frontera
If thrombolytic induced coagulopathy occurs, the manual
suggests stopping medication, administration of 12 U of
cryoprecipitate (to replace ﬁbrinogen and factor VIII) as well
as 6–8 U of platelets [6].
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 2 7 8 – 2 8 92865. Aspirin and other platelet aggregation
inhibitors (antiplatelet drugs)
See Table 5.
5.1. Summary of product characteristics
5.1.1. Aspirin
For ICrH – measures were not speciﬁed [29].
The manufacturers specify only the therapeutic measures
in overdose and intoxication cases.
The Polish SPC states that the intoxication might occur if
aspirin dose is higher than 100 mg/kg/24 h for more than 2
days. In overdose cases – despite the speciﬁc treatment of ICrH,
the treatment of associated acidosis is advised: gastric lavage,
repeated administration of activated charcoal, forced alkaline
diuresis. Tachypnea, hyperventilation, respiratory alkalosis:
ﬂuid and electrolyte management, hemodialysis in severe
cases. Respiratory alkalosis with compensatory metabolic
acidosis, ﬂuid and electrolyte loss, dehydration, oliguria to
renal failure as well as hyperpyrexia: ﬂuid and electrolyte
management [29].
The British SPC [30] states that salicylate poisoning is
usually associated with plasma concentrations >350 mg/L.
Single doses less than 100 mg/kg are unlikely to cause serious
poisoning. Give activated charcoal if an adult presents within
1 h of ingestion of more than 250 mg/kg. The plasma salicylate
concentration should be measured, although the severity of
poisoning cannot be determined from this alone and the
clinical and biochemical features must be taken into account.
Elimination is increased by urinary alkalinization, which is
achieved by the administration of 1.26% sodium bicarbonate.
The urine pH should be monitored. Correct metabolic acidosis
with intravenous 8.4% sodium bicarbonate (ﬁrst check serum
potassium). Forced diuresis should not be used since it does
not enhance salicylate excretion and may cause pulmonary
edema.
Haemodialysis or haemoperfusion are effective methods of
removing salicylate from plasma, however, haemodyalisis is
the treatment of choice for severe poisoning and should beTable 5 – The management of antiplatelet drugs-associated IC
SPC* [29–35] PNA [1] ESO 
Aspirin: GL, AC, forced alkaline diuresisa,
hemodialysis and hemoperfusion
(severe cases), control the plasma
salicylate concentration, urine pH
monitoring, metabolic acidosis correction
Clopidogrel: PT
Prasugrel: Platelet and/or other blood
products transfusion
Ticagrelor: local standard medical
practice
Temporal drug
withdrawal
No spe
guideli
GL – gastric lavage, AC – activated charcoal, PT – platelet transfusion, DD
a Forced alkaline diuresis is recommended by the Polish SPC [29]. Accord
recommends urine alkalinization [30].
* SPCs specify only the therapeutic measures in overdose and intoxicatioconsidered in patients with plasma-salicylate concentrations
>700 mg/L (5.1 mmol/L), or lower concentrations associated
with severe clinical or metabolic features. Patients under
10 years or over 70 have increased risk of salicylate toxicity and
may require dialysis at an earlier stage [30].
5.1.2. Clopidogrel
The Polish [31] and European [32] SPCs state that appropriate
therapy should be considered if bleeding is observed. If prompt
correction of prolonged bleeding time is required, platelet
transfusion may reverse the effects of clopidogrel.
5.1.3. Prasugrel
According to Polish [33] and European [34] SPCs, no data are
available on the reversal of the pharmacological effect of
prasugrel; however, if prompt correction of prolonged bleeding
time is required, platelet transfusion and/or other blood
products may be considered.
5.1.4. Ticagrelor
The European SPC [35] states that there is currently no known
antidote to reverse the effects of ticagrelor, and ticagrelor is
not expected to be dialysable. Treatment of overdose should
follow local standard medical practice.
It is worth noting that prasugrel and ticagrelor have been
increasingly employed in patients with acute coronary
syndromes, therefore management of these drugs – associated
ICrH would be very important for every-day clinical practice.
5.2. Polish Neurological Association
According to the guidelines of the Polish Neurological Association
Vascular Diseases Section Expert Group 2012 [1], the antiplatelet
drug has to be temporarily withheld.
5.3. European Stroke Organisation
European Stroke Organization guidelines for the management of
spontaneous intracerebral hemorrhage [2] state that in the
absence of RCTs, the ESO cannot make strong recommenda-
tions about how, when, and for whom to normalize clotting inrH.
[2] AHA/ASA [3] Manual by
Wijdicks [4]
Wijdicks
NCC [5]
Frontera [6]
ciﬁc
nes
No speciﬁc
guidelines
PT No speciﬁc
guidelines
DDAVP, PT
AVP – desmopresin acetate.
ing to British version, forced diuresis should not be used, however it
n.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 2 7 8 – 2 8 9 287patients with acute spontaneous ICeH who had been on
antiplatelet drugs.
Additional information by ESO: The concept of platelet
transfusion in patients with spontaneous ICeH in association
with antiplatelet drug use is to replace nonfunctional
thrombocytes with functional thrombocytes and thus to
increase the chance of hemostasis. ESO found one RCT
(n = 22) on the use of thrombocytes in traumatic ICeH. In this
RCT, platelet transfusion had no effect on platelet function or
ICeH progression. However, the small size of this RCT or the
use of only 1 U of platelets may explain these ﬁndings. Two
RCTs of platelet transfusion in ICeH are ongoing (NCT00699621
and The Netherlands National Trial Register NTR1303).
5.4. AHA/ASA
According to AHA/ASA [3] the usefulness of platelet transfu-
sions in ICeH patients with a history of antiplatelet use is
unclear and is considered investigational. There are no speciﬁc
therapeutic guidelines.
5.5. Manual by Frontera
Coagulopathy by aspirin (acetylosalicylic acid) and, nonsteroi-
dal anti-inﬂammatory drugs (NSAID) or platelet aggregation
inhibitors (clopidogrel, ticlopidine).
Therapeutic options: Desmopresin acetate (DDAVP) 0.3 mg/
kg i.v.  1 (20 mg in 50 ml normal saline over 15–30 min) and
transfuse 5–6 U of platelets.
Comments: Aspirin and NSAID irreversibly block platelet
cyclooxygenase, inhibiting the production of thromboxane A2,
resulting in the inhibition of platelet aggregation for up to 7–10
days.
Clopidogrel and ticlopidine alter platelet aggregability by
irreversibly inhibiting the surface ADP binging site and by
reducing ADP release from activated platelets [6].
5.6. Manual by Wijdicks
Wijdicks (2014) states the following: ‘‘Whether platelet
transfusions are needed in patients with ICrH and in whom
prior antiplatelet use is unresolved, but one study suggested
the improvement of platelet assays with two packs (containing
6 U) of apharesis platelets. Transfusion of 6 U of platelets
should raise the platelet count by 60,000/mL–1 U increase by
10,000 mL’’ [4].
‘‘A considerable number of donor units may be needed to
reverse the combined antiaggregant effect of aspirin and
clopidogrel. One study in volunteers found 10 donors units for
300 mg, but only 15 U for 600 mg of clopidogrel were needed to
completely reverse antiplatelet effect, thus suggesting a
nonlinear therapeutic effect’’ [36].
5.7. Comments
The treatment options for the reversal of anticoagulation after
intracranial hemorrhage differs considerably between sources.
Some of them, mainly SPCs do not refer directly to
intracerebral or intracranial hemorrhage, providing only gener-
al recommendations about hemorrhage during antiplateletdrug usage (especially acetylsalicylic acid, Aspirin) [29,30].
Therefore, such SPCs may be insufﬁciently valuable in
neurological or neurosurgical practice for managing ICrH or
ICeH patients. Additionally, Polish SPC differ in detail from the
British or European versions. The differences are not crucial, but
a lack of cohesion in SPCs is unfavorable, especially nowadays
when we are facing increasing movement of patients among
European countries. Therefore, it would be safer for health
professionals and patients if all SPCs in European Union
countries were harmonized.
In the case of platelet aggregation inhibitors (acetylsalicylic
acid and clopidogrel) associated with cerebral hemorrhage,
therapeutic suggestions by Wijdicks and ESO state that
treatment with transfused higher doses of platelet units after
clopidogrel would most likely be sufﬁcient to reverse the
antiplatelet effect [2,4,31,32].
The SPCs concerning other conditions in this paper were
disappointingly inconclusive on many points; however, the
review of the literature showed some progress.
The largest divergence in the above presented opinions was
observed in the remarks about NOAC-associated hemor-
rhages: Wijdicks stated that rFVIIa as well as FFP does not
reverse the anticoagulant effect of those drugs, whereas the
manual edited by Frontera advised an increase in other
coagulation factors with rFVIIa or PCC/FFP; in fact, both agreed
that PCC could be worth considering and may be potentially
effective [4,6].
It is also worth noting that for adults with acute
spontaneous ICeH that is not associated with antithrombotic
drug the ESO does not recommend the use of rFVIIa outside of
ongoing trials [2].
Generally, our overview allowed us to determine that both
European and American guidelines based on EBM are
intelligible; however, they are often less useful in every-day
clinical practice where practitioners are obliged to save patient
lives and improve their conditions using any available and
reasonable measures. The experts' opinions are more far-
sighted in terms of emergency clinical practice. However, we
still should bear in mind that such opinions mirror those of
one (although usually very prominent) center's experience.
Those expert opinions, although based on insufﬁcient RTC
data, could be valuable for acute emergency physicians who
encounter this clinical situation.
Currently, there are no generally accepted opinions con-
cerning most of the reviewed agents in this ﬁeld, mainly due to
a shortage of well-designed, methodologically satisfactory
studies. On the one hand, they are extremely difﬁcult to
conduct; therefore, we most likely should rely on the longest
available case series, which may be informative in terms of
emergency treatment strategies.
There is a strong need for the continuation of large
multicenter and international trials in this ﬁeld as well as for
pursuing multicenter databases. This should be helpful for the
present lack of clinical trials with sufﬁcient statistical power.
Important note
The authors and publisher of this paper have checked with
sources believed to be reliable in their efforts to provide
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accepted at the time of publication.
However in light of the possibility of human error or
changes in the practice of medicine, neither the authors, nor
the publisher, not any other party who has been involved in
the preparation or publication of this paper warrants that the
information contained herein is in every respect accurate or
complete.
Readers are encouraged to conﬁrm the information con-
tained herein with other reliable sources, and are strongly
advised to check the product information sheet provided by
the pharmaceutical company for each drug they plan to
administer.
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